<DOC>
	<DOCNO>NCT01392742</DOCNO>
	<brief_summary>This observational study evaluate predictor early on-treatment response sustain virological response patient chronic hepatitis C receive Pegasys ( peginterferon alfa-2a ) ribavirin . Data collect patient treatment ( 24 48 week ) 24 week end treatment .</brief_summary>
	<brief_title>An Observational Study Predictive Factors Response Patients With Chronic Hepatitis C Treated With Pegasys ( Peginterferon Alfa-2a ) Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Serologically confirm chronic hepatitis C ( genotype ) Treatment Pegasys ribavirin accord current standard care line current summary product characteristic ( SPCs ) /local label Coinfection HIV and/or hepatitis B Contraindications accord SPC Pegasys/ribavirin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>